Bristol Myers Squibb Invests $100M in BioArctic for Next-Generation Alzheimer’s Therapies

Collaboration Agreement:
Bristol Myers Squibb has entered into a collaboration agreement with BioArctic, the original developer of Leqembi, to license two preclinical antibodies, BAN1503 and BAN2803, for the treatment of Alzheimer's disease13.

Financial Terms:
Bristol Myers Squibb will pay BioArctic $100 million upfront as part of the agreement13.

Background on Leqembi:
Leqembi (lecanemab) is a humanized amyloid-beta monoclonal antibody developed by Eisai and BioArctic. It has been approved for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients, particularly those with apolipoprotein E ε4 (ApoE ε4)2.

Eisai and BioArctic Collaboration:
Eisai and BioArctic have a long-term collaboration for the development and commercialization of Alzheimer's disease treatments, including Leqembi, since 20052.

Bristol Myers Squibb's Strategy:
This deal marks Bristol Myers Squibb's push into Alzheimer's disease research, leveraging BioArctic's expertise in developing next-generation therapies13.

Sources:

1. https://endpts.com/bristol-myers-pays-100m-upfront-to-collaborate-with-leqembi-originator-in-alzheimers/

2. https://investors.biogen.com/news-releases/news-release-details/leqembir-lecanemab-authorized-early-alzheimers-disease-great

3. https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-896352512.jpg?VersionId=7TQhEcvGoObyTjaGsvQFSOFbea3reig&sa=X&ved=2ahUKEwiWp-qZgNGKAxWJGtAFHTlcB40QB16BAgJEAI